Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 884 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Coagulation Disorders Clear all
Completed No phase listed Observational

Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial (CAF-PINT)

NCT01892969
View directory record Official record
Conditions
Heart Failure, Respiratory Failure
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
14 Days to 18 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Los Angeles, California • Oakland, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 14, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

NCT03333486
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
1 Year to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 14, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Performance Evaluation of T-TAS 01 PL Chip

NCT03621020
View directory record Official record
Conditions
Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
Interventions
T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
21 Years and older
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
5
States / cities
San Francisco, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 14, 2026, 4:55 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Pirfenidone Treatment in HPS-ILD

NCT04193592
View directory record Official record
Conditions
Hermansky Pudlak Syndrome, Interstitial Lung Disease
Interventions
Pirfenidone
Drug
Lead sponsor
Jesse Roman
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tranexamic Acid Pharmacokinetics During Postpartum Hemorrhage

NCT03863964
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
blood test
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 14, 2026, 4:55 PM EDT
Recruiting No phase listed Observational

Investigation of the Genetics of Hematologic Diseases

NCT02720679
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Erythrocyte Disorder, Leukocyte Disorder, Hemostasis, Blood Coagulation Disorder, Sickle Cell Disease, Dyskeratosis Congenita, Diamond-Blackfan Anemia, Congenital Thrombocytopenia, Severe Congenital Neutropenia, Fanconi Anemia, Myelodysplastic Syndromes, Myeloproliferative Diseases
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2050
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 14, 2026, 4:55 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04224688
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
St. Petersburg, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 14, 2026, 4:55 PM EDT
Completed No phase listed Observational

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

NCT02953704
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Not listed
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
114
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

A Study in Myeloproliferative Disorders

NCT01134120
View directory record Official record
Conditions
Myeloproliferative Disorders, Thrombocythemia, Essential, Polycythemia Vera, Primary Myelofibrosis
Interventions
LY2784544
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Not applicable Interventional

The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery

NCT03897621
View directory record Official record
Conditions
Coagulation; Intravascular, Rotational Thromboelastometry, Fibrinolysis; Hemorrhage, Tranexamic Acid, Total Hip Arthroplasty
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Not applicable Interventional

Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy

NCT05486338
View directory record Official record
Conditions
Obesity, Adiposity
Interventions
Hybrid Argon Plasma Coagulation (HAPC)
Device
Lead sponsor
Erbe Elektromedizin GmbH
Industry
Eligibility
22 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Not applicable Interventional

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)

NCT01051076
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
VWF/FVIII concentrates
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00713193
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Cyclosporine, Prednisone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

rVWF IN PROPHYLAXIS

NCT02973087
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Phase 3 Interventional

Oral Vitamin K for Warfarin Associated Coagulopathy

NCT00143715
View directory record Official record
Conditions
Coagulation, Bleeding, Thrombosis
Interventions
Phytonadione (Vitamin K1)
Drug
Lead sponsor
St. Joseph's Healthcare Hamilton
Other
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Westminster, Colorado • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 14, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

NCT07575308
View directory record Official record
Conditions
Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
Interventions
ALN-6400
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Orange, California • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 4:55 PM EDT
Withdrawn Phase 3 Interventional

Emicizumab PUPs and Nuwiq ITI Study

NCT04030052
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 14, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias

NCT05502783
View directory record Official record
Conditions
Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions
fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 14, 2026, 4:55 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

NCT00251277
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

NCT00005967
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 14, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

NCT00666211
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
educational intervention, Titrated pain management, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Hopkinsville, Kentucky • Owensboro, Kentucky • Chattanooga, Tennessee + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 14, 2026, 4:55 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Coagulation and Fibrinolysis of Estradiol in Transwomen

NCT05387577
View directory record Official record
Conditions
Transgenderism, Clotting Disorder
Interventions
Estradiol Tablets, Transdermal patch
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 14, 2026, 4:55 PM EDT
Active, not recruiting No phase listed Observational

An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related

NCT06765681
View directory record Official record
Conditions
Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation
Interventions
Diagnosis of both VTE and sepsis
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 14, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-Injury Platelet Biology: Mechanisms and Outcomes

NCT03682757
View directory record Official record
Conditions
Wound and Injuries, Blood Platelets, Endothelium
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 14, 2026, 4:55 PM EDT